Equities

Sonoma Pharmaceuticals Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Sonoma Pharmaceuticals Inc

Actions
  • Price (EUR)2.60
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change--
  • Beta1.6642
Data delayed at least 15 minutes, as of Sep 10 2024 07:35 BST.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Sonoma Pharmaceuticals, Inc. is a global healthcare company. The Company is engaged in developing and producing stabilized hypochlorous acid (HOCl) products for a range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Its products are all classified as medical devices and categorized as prescription, over-the-counter (OTC) and office dispense products. It offers both prescription and OTC dermatology products, including Epicyn Facial Cleanser, Levicyn Dermal Spray, Levicyn Gel, Levicyn Spray Gel, Celacyn Scar Management Gel. In the United States, it offers Microcyn wound and skin care both as an OTC and prescription product. Its eyecare products include Acuiycn Eyelid and Eyelash Hygiene, and Ocucyn Eyelid and Eyelash Cleanser. MicrocynAH is an HOCl-based topical product that cleans, debrides and treats a wide spectrum of animal wounds and infections.

  • Revenue in USD (TTM)17.72m
  • Net income in USD-3.37m
  • Incorporated2006
  • Employees168.00
  • Location
    Sonoma Pharmaceuticals Inc5445 CONESTOGA COURT, SUITE 150BOULDER 80301United StatesUSA
  • Phone+1 (617) 243-0050
  • Fax+1 (707) 283-0551
  • Websitehttps://sonomapharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.